Opus Genetics announced a $155 million non‑dilutive financing agreement with Oberland Capital Management LLC that will provide the company with up to $155 million in capital. The deal begins with an initial $35 million senior note and a $5 million equity investment priced at $4.48 per share, with additional tranches of up to $35 million each available at the company’s option within twelve months and milestone‑linked tranches. A further $50 million of tranches may be provided by mutual agreement, giving Opus Genetics significant flexibility to fund its clinical‑stage gene‑therapy programs.
The financing is designed to extend Opus Genetics’ cash runway to 2029, supporting the expected completion of pivotal studies for its lead programs, OPGx‑LCA5 and OPGx‑BEST1, and enabling earlier‑stage candidates such as RDH12, MERTK, and RHO to enter clinical testing. The company’s strategy is to leverage its commercial phentolamine franchise to finance a high‑value gene‑therapy pipeline, a model that has already attracted investor confidence. As CEO George Magrath noted, “With the early success of the LCA5 and BEST1 programs, we are at a pivotal moment in which acceleration of our pipeline can drive significant future value. This credit facility enables us to fully fund clinical development and initiate pre‑launch activities for our BEST1 and LCA5 programs, as well as move the earlier‑stage RDH12, MERTK, and RHO programs into the clinic.”
Prior to this financing, Opus Genetics had $45.1 million in cash and cash equivalents as of December 31, 2025, and after a $25 million private placement the total cash resources rose to $70.1 million, sufficient to fund operations into the first half of 2028. The new $155 million tranche therefore provides a substantial buffer that will allow the company to focus on clinical development without immediate dilution of shareholders. Oberland Capital’s partner William Clifford added, “Opus Genetics’ validated gene therapy platform represents one of the most promising approaches for restoring vision and preventing blindness in patients suffering from severe inherited retinal diseases and fully aligns with our investment strategy of partnering with companies developing innovative technologies that address areas of high unmet medical need.”
The financing agreement is expected to close on April 20, 2026, and the structure’s milestone‑linked tranches align investor capital with Opus Genetics’ progress, reducing risk for both parties. By securing non‑dilutive capital, the company can accelerate its pipeline, potentially shortening the time to regulatory approval and market entry for its gene‑therapy candidates, which could translate into significant long‑term value for stakeholders.
The deal underscores Opus Genetics’ ability to combine a commercial product line with a high‑growth gene‑therapy pipeline, positioning it as a leading player in the inherited retinal disease market and reinforcing investor confidence in its strategic execution.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.